Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho Selecting Candidates for NHI Re-pricing
January 16, 2006
- Flu Season Begins Six Weeks Early: Korosho
January 16, 2006
- NDA Filed for Anti-RA Adalimumab: Eisai, Abbott Japan
January 16, 2006
- First Anti-cancer Pharmacotherapy Specialists to Be Certified by the JSMO in April
January 16, 2006
- Astellas' Hyponatremia Treatment Vaprisol Approved in the US
January 16, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 16, 2006
- Novartis Files NDA for Additional Indication of Glivec
January 16, 2006
- SURVEY 3 articles
January 16, 2006
- Peg-Intron, Rebetol Combination Granted Additional Indication
January 16, 2006
- Aricept Orodispersible Tablet Completes MRP in 12 EU Countries
January 16, 2006
- REGULATORY NEWS IN BRIEF
January 16, 2006
- Nippon Shinyaku Licenses CML Treatment NS-187 to INNOVIVE of the US
January 16, 2006
- BUSINESS NEWS IN BRIEF
January 16, 2006
- SELF-MEDICATION NEWS IN BRIEF
January 16, 2006
- 3 Associations Draft Proposal on Med. Device Safety Management
January 9, 2006
- STATISTICS
January 9, 2006
- ACCJ Calls For Improvement in Review of Medical Devices
January 9, 2006
- ＜New Year's Greeting＞PhRMA to Work to More Quickly Bring Innovative Drugs to Patients
January 9, 2006
- MEDICAL DEVICE NEWS IN BRIEF
January 9, 2006
- Surprise Free Forecasts For 2006
January 9, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…